Skip to main content

ekterly

Generic: sebetralstat

ekterly: sourced relationships with 1 company · 1 FDA decision.

ekterly evidence translation

What we can confirm

What it means

Source-backed records connect ekterly to KALV; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could ekterly → KALV affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
KalVista Pharmaceuticals, Inc. (KALV)
licensee · Reported 2025-07-10 · Current development: unknownSource
acute attacks of hereditary angioedema (HAE) in adult and pe…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY ® is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ( 1 )(KALV)FDA ↗
NDA219301Type 1 - New Molecular EntityOrphan DrugStandardOralTablet

Frequently asked questions

Which companies have sourced relationships with ekterly?

ekterly has dated SEC/FDA relationship records for KalVista Pharmaceuticals, Inc..

What is ekterly's latest FDA decision?

The most recent tracked FDA decision for ekterly is Approval for 1 INDICATIONS AND USAGE EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY ® is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ( 1 ), dated July 3, 2025.